rs1059369 — GDF15 S48T

GDF15 signal-peptide missense variant that tags a haplotype influencing circulating GDF15 levels — a stress-responsive cytokine driving appetite suppression, nausea, and cardiometabolic stress signaling via the brainstem GFRAL receptor

See your personal result for GDF15

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

GDF15 S48T — Reading the Body's Distress Signal

GDF15, once called macrophage inhibitory cytokine-1 or MIC-111 macrophage inhibitory cytokine-1 or MIC-1
GDF15 was independently discovered several times and given different names: MIC-1, NAG-1, PLAB, and PDF. All refer to the same gene on chromosome 19, is one of the most versatile stress signals in human biology. Produced at low levels by most organs under normal conditions, it surges in response to cellular injury, metabolic overload, inflammation, pregnancy, and cancer. Once released into the bloodstream, it crosses into the brainstem where it binds the GFRAL receptor22 GFRAL receptor
Glial cell line-derived neurotrophic factor family receptor alpha-like — expressed almost exclusively in the area postrema and nucleus tractus solitarii, the brainstem regions that coordinate nausea and appetite suppression, recruiting the co-receptor RET to trigger appetite suppression, nausea, and reduced food intake. It also serves as a potent biomarker: elevated circulating GDF15 consistently predicts all-cause mortality, cardiovascular events, and metabolic dysfunction. The rs1059369 (S48T) variant sits in the coding region of GDF15, and its genetic context — the haplotype it tags — modulates how much of this stress signal your body produces.

The Mechanism

The rs1059369 variant converts serine to threonine at position 48 of the GDF15 preproprotein (NM_004864.4:c.142T>A, p.Ser48Thr). Position 48 falls within the signal peptide and propeptide region33 signal peptide and propeptide region
GDF15 is synthesized as a 308-amino-acid preproprotein. The signal peptide (~28 aa) directs the protein to the secretory pathway; the propeptide (~167 aa) is cleaved by furin-like proteases before the mature 112-amino-acid dimer is secreted — the portion of the protein that is cleaved before secretion. The serine-to-threonine substitution is chemically conservative (both hydroxyl-bearing), and the S48T change alone is not predicted to substantially alter the mature secreted protein's structure or receptor binding.

The variant's primary role is as a haplotype tag44 haplotype tag
A SNP that reliably tracks another nearby variant through linkage disequilibrium — the non-random co-inheritance of nearby genetic variants. A three-SNP study of the GDF15 locus in hypertensive patients found that rs1059369 tags a haplotype anchored by the -3148C>G promoter variant (rs4808793), which increases GDF15 transcriptional activity 1.45-fold at baseline and 1.73-fold under adrenergic stimulation. The A allele at rs1059369 co-segregates with the G allele at rs4808793 in a haplotype associated with higher plasma GDF15 and more favorable cardiac remodeling. The functional driver appears to be the promoter variant; rs1059369 is the coding-region marker that travels with it.

The Evidence

Wang et al. (2009)55 Wang et al. (2009)
Wang X et al. The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension. Clin Sci (Lond), 2009 genotyped 1,527 hypertensive patients for three GDF15 variants including rs1059369 (+157A>T). The haplotype carrying the A allele was associated with a 25% lower odds of left ventricular hypertrophy (OR=0.75, 95% CI 0.63-0.89, P=0.0009), and carriers showed significantly higher circulating GDF15 levels (P=0.04). This suggests that the A-allele haplotype upregulates GDF15 expression, and that moderately elevated GDF15 is cardioprotective in the hypertensive context — consistent with GDF15's known role in anti-hypertrophic signaling in the heart.

A large integrated analysis by Lemmelä et al. (2022)66 Lemmelä et al. (2022)
Lemmelä S et al. Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans. eLife, 2022 across 14,099 individuals found that circulating GDF15 predicts all-cause mortality, cardiometabolic disease, respiratory illness, and psychiatric disorders, but Mendelian randomization did not support elevated GDF15 as a causal driver of cardiometabolic disease. Instead, GDF15 rises in response to metabolic stress (including obesity, which causally elevates GDF15, IVW pFDR = 0.0040). The picture is that of a biomarker reading, not a culprit — though the GFRAL-mediated appetite suppression pathway is real and pharmacologically targetable.

In pregnancy, where GDF15 rises dramatically and drives nausea via the GFRAL receptor, Pereira et al. (2026)77 Pereira et al. (2026)
Pereira DA et al. Functional characterization of the GWAS lead SNP rs888663 and effects of GDF15 SNPs on GDF15 levels in gestational hypertension and preeclampsia. Mol Biol Rep, 2026 found that TT genotype carriers with preeclampsia or gestational hypertension had lower GDF15 levels than healthy pregnant TT carriers (P<0.05), linking rs1059369 genotype to gestational GDF15 regulation in pathological pregnancies.

Practical Actions

For TT individuals (the common genotype), no specific GDF15-related intervention is needed. The TT genotype produces typical GDF15 stress signaling. For AT and AA carriers, the A allele haplotype is associated with higher circulating GDF15 at baseline, which in the context of metabolic stress (obesity, hypertension, inflammatory conditions) could influence appetite regulation, nausea sensitivity, and cardiac remodeling. Notably, GDF15 is one of the mechanisms by which metformin reduces appetite and body weight — carriers with higher GDF15 may have a more pronounced response to this mechanism.

Because GDF15 is fundamentally a stress-response biomarker, the most actionable insight is using it as a monitoring tool: elevated circulating GDF15 (above ~600 pg/mL in non-pregnant adults) signals metabolic or inflammatory stress and warrants investigation of its cause.

Interactions

rs1059369 is in linkage disequilibrium with rs4808793 (GDF15 promoter) and rs1058587 (H202D, the major GWAS variant for circulating GDF15 levels). The A allele at rs1059369 co-travels with the protective haplotype identified by Wang et al. The most important related variant is rs1058587 (H202D): this variant's G allele is present in approximately 21% of Europeans and substantially affects assay-measured GDF15 levels due to epitope interference — a nuance relevant to interpreting commercial GDF15 blood tests rather than biology per se. For individuals tracking GDF15 as a longevity biomarker, the rs1058587 H202D status is more informative than rs1059369.

Genotype Interpretations

What each possible genotype means for this variant.

TT Standard GDF15 Output Normal

Common genotype — typical GDF15 stress signaling

You have two copies of the reference T allele (Ser48 form). This is the most common genotype globally, carried by about 61% of the general population and roughly 61% of Europeans. Your GDF15 gene produces standard baseline levels of this stress-response cytokine, rising appropriately during illness, metabolic overload, pregnancy, and cardiac stress.

This genotype does not confer the haplotype-linked elevation in resting GDF15 expression associated with the A allele. In the context of preeclampsia and gestational hypertension, TT carriers with these conditions show notably lower GDF15 levels than healthy TT pregnant women, suggesting that inflammatory or vascular conditions that would normally drive GDF15 up are not doing so as strongly in this genotype.

AT Elevated GDF15 Haplotype — Heterozygous Intermediate

One copy of the A allele — part of a haplotype associated with higher GDF15 expression

The functional link between rs1059369 and GDF15 expression is mediated by the haplotype it tags. The S48T change itself (serine to threonine) is chemically conservative and falls within the signal/propeptide region that is cleaved before secretion — unlikely to substantially alter mature GDF15 biology directly. The expression effect originates from the linked promoter variant rs4808793 (-3148G), which increases GDF15 transcription 1.45-fold at baseline and 1.73-fold under adrenergic stimulation.

Elevated GDF15 in the setting of cardiac stress signals through anti-hypertrophic pathways. In the hypertensive cohort studied by Wang et al., haplotype A carriers (including AT heterozygotes) had a 25% lower odds of left ventricular hypertrophy than TT homozygotes, consistent with GDF15's known cardioprotective role in the hypertensive heart.

In metabolic contexts, GDF15 is one of the key mediators of appetite suppression — both during illness (explaining the anorexia of acute inflammation) and pharmacologically (explaining part of metformin's appetite-reducing effect). Higher baseline GDF15 expression from the A-allele haplotype may translate to modestly greater appetite suppression under metabolic stress conditions.

AA Elevated GDF15 Haplotype — Homozygous High

Two copies of the A allele — haplotype associated with the highest GDF15 expression and reduced left ventricular hypertrophy risk

Homozygous AA individuals carry two copies of the haplotype that upregulates GDF15 transcription through the linked -3148G promoter variant. This means both chromosomal copies of GDF15 are under higher promoter drive, producing the most elevated baseline GDF15 levels of any genotype.

In practical terms, your GDF15 stress-response system is more active at baseline. During acute illness, metabolic stress, intensive exercise, or pregnancy, GDF15 will rise from a higher starting point, amplifying its downstream effects: appetite suppression via GFRAL, reduced gastric motility (contributing to nausea), and anti-hypertrophic cardiac signaling.

The flip side is that your higher baseline GDF15 may contribute to greater nausea sensitivity — whether during pregnancy (where GDF15 drives hyperemesis), during chemotherapy (GDF15 mediates treatment-induced nausea), or with drugs like metformin and GLP-1 agonists that raise GDF15 as part of their mechanism. This is not adverse in itself — the nausea response is what reduces caloric intake — but it is worth anticipating.

From a cardiovascular perspective, higher GDF15 in the context of hypertension appears protective against pathological cardiac remodeling. The anti-hypertrophic signaling of GDF15 in cardiomyocytes counteracts the pressure-overload-driven enlargement that increases heart failure risk.